Literature DB >> 29242296

Promising activity of selinexor in the treatment of a patient with refractory diffuse large B-cell lymphoma and central nervous system involvement.

Sabela Bobillo1, Pau Abrisqueta1, Cecilia Carpio1, Priyanka Raheja1, Josep Castellví2, Marta Crespo3, Francesc Bosch4,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29242296      PMCID： PMC5792294          DOI： 10.3324/haematol.2017.181636

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  9 in total

Review 1.  Accumulating active p53 in the nucleus by inhibition of nuclear export: a novel strategy to promote the p53 tumor suppressor function.

Authors:  S Laín; D Xirodimas; D P Lane
Journal:  Exp Cell Res       Date:  1999-12-15       Impact factor: 3.905

2.  Preclinical antitumor efficacy of selective exportin 1 inhibitors in glioblastoma.

Authors:  Adam L Green; Shakti H Ramkissoon; Dilara McCauley; Kristen Jones; Jennifer A Perry; Jessie Hao-Ru Hsu; Lori A Ramkissoon; Cecile L Maire; Benjamin Hubbell-Engler; David S Knoff; Sharon Shacham; Keith L Ligon; Andrew L Kung
Journal:  Neuro Oncol       Date:  2014-11-02       Impact factor: 12.300

Review 3.  Nuclear transport and cancer: from mechanism to intervention.

Authors:  Tweeny R Kau; Jeffrey C Way; Pamela A Silver
Journal:  Nat Rev Cancer       Date:  2004-02       Impact factor: 60.716

Review 4.  Central nervous system involvement in diffuse large B-cell lymphoma: an analysis of risks and prevention strategies in the post-rituximab era.

Authors:  Christopher D Fletcher; Brad S Kahl
Journal:  Leuk Lymphoma       Date:  2014-02-24

5.  First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors.

Authors:  Albiruni R Abdul Razak; Morten Mau-Soerensen; Nashat Y Gabrail; John F Gerecitano; Anthony F Shields; Thaddeus J Unger; Jean R Saint-Martin; Robert Carlson; Yosef Landesman; Dilara McCauley; Tami Rashal; Ulrik Lassen; Richard Kim; Lee-Anne Stayner; Mansoor R Mirza; Michael Kauffman; Sharon Shacham; Amit Mahipal
Journal:  J Clin Oncol       Date:  2016-10-31       Impact factor: 44.544

Review 6.  CNS prophylaxis in lymphoma: who to target and what therapy to use.

Authors:  Quentin A Hill; Roger G Owen
Journal:  Blood Rev       Date:  2006-08-01       Impact factor: 8.250

7.  Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma.

Authors:  John Kuruvilla; Michael Savona; Rachid Baz; Paul Morten Mau-Sorensen; Nashat Gabrail; Ramiro Garzon; Richard Stone; Michael Wang; Lynn Savoie; Peter Martin; Ian Flinn; Meagan Jacoby; Thaddeus J Unger; Jean-Richard Saint-Martin; Tami Rashal; Sharon Friedlander; Robert Carlson; Michael Kauffman; Sharon Shacham; Martin Gutierrez
Journal:  Blood       Date:  2017-05-03       Impact factor: 22.113

8.  CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications.

Authors:  Y-T Tai; Y Landesman; C Acharya; Y Calle; M Y Zhong; M Cea; D Tannenbaum; A Cagnetta; M Reagan; A A Munshi; W Senapedis; J R Saint-Martin; T Kashyap; S Shacham; M Kauffman; Y Gu; L Wu; I Ghobrial; F Zhan; A L Kung; S A Schey; P Richardson; N C Munshi; K C Anderson
Journal:  Leukemia       Date:  2013-04-16       Impact factor: 11.528

9.  How I treat CNS lymphomas.

Authors:  James L Rubenstein; Neel K Gupta; Gabriel N Mannis; Amanda K Lamarre; Patrick Treseler
Journal:  Blood       Date:  2013-08-20       Impact factor: 22.113
  9 in total
  6 in total

1.  Rational targeted therapeutics for double-hit lymphoma.

Authors:  Nancy G Azizian; Yuanhui Liu; Lan V Pham; Yulin Li
Journal:  Int J Hematol Oncol       Date:  2019-08-21

Review 2.  Targeting nuclear import and export in hematological malignancies.

Authors:  Boaz Nachmias; Aaron D Schimmer
Journal:  Leukemia       Date:  2020-07-05       Impact factor: 11.528

Review 3.  Novel insights into the biomarkers and therapies for primary central nervous system lymphoma.

Authors:  Yujia Zhai; Xiangxiang Zhou; Xin Wang
Journal:  Ther Adv Med Oncol       Date:  2022-05-04       Impact factor: 5.485

4.  Secondary CNS myeloma with remission after systemic CNS-penetrating agents.

Authors:  Luis G Fernandez; Daniel Eduardo Oyon; Vinai Gondi; Sean Grimm; Osaama H Khan
Journal:  Neurooncol Adv       Date:  2022-07-01

5.  Feasibility study of using high-throughput drug sensitivity testing to target recurrent glioblastoma stem cells for individualized treatment.

Authors:  Erlend Skaga; Evgeny Kulesskiy; Marit Brynjulvsen; Cecilie J Sandberg; Swapnil Potdar; Iver A Langmoen; Aki Laakso; Emília Gaál-Paavola; Markus Perola; Krister Wennerberg; Einar O Vik-Mo
Journal:  Clin Transl Med       Date:  2019-12-30

6.  Simultaneous targeting of XPO1 and BCL2 as an effective treatment strategy for double-hit lymphoma.

Authors:  Yuanhui Liu; Nancy G Azizian; Yaling Dou; Lan V Pham; Yulin Li
Journal:  J Hematol Oncol       Date:  2019-11-21       Impact factor: 17.388
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.